Pharma News

Researchers have found murine leukemia viruses (MLV) related gene sequences in blood samples collected from patients diagnosed with chronic fatigue syndrome (CFS) and some healthy blood donors, according to a study published online today by the scientific journal Proceedings of the National Academy of Sciences (PNAS).

There is a direct and linear association between plasma beta-amyloid (Aβ) levels and multiple aspects of cognitive decline over time, including cognitive changes that constitute conversion to Alzheimer's disease, according to new findings from a population-based, ethnically diverse longitudinal sample of older adults.

Despite denials by the Government and stern measures including the introduction of special barcode, the supply of sub-standard drugs for the Central Government Health Scheme (CGHS) and pilferage of drugs continue in many places, it is learnt.

Prophylactic gentamicin-collagen sponges do not appear to significantly decrease infection rate compared with no intervention in patients undergoing colorectal surgery, according to the findings of a large randomized phase 3 trial.

Bayer Schering Pharma AG, Berlin, Germany, announced that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the US for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging (MRI).

[adsense:336x280:8701650588]

In patients with mild Alzheimer's disease (AD), deep brain stimulation (DBS) modulates specific brain circuits important in memory and is safe, according to results of the first phase 1 study of DBS for AD, published online July 30 in the Annals of Neurology.

People infected with Hepatitis B virus are around twice as likely to develop non-Hodgkin Lymphoma, according to a study published in Lancet Oncology. Hepatitis B was already known to cause liver cancer, and some scientists had suspected it might cause lymphoma.

Merck said that its hepatitis C drug boceprevir hit its primary endpoints in two Phase III studies and will file for an approval of the potential blockbuster by the end of this year. And analysts quickly began to handicap Merck's chances against Vertex, which has compiled a mountain of positive data for its hep C drug telaprevir.

[adsense:336x280:8701650588]